(Q46270437)

English

Rucaparib maintenance treatment for recurrent ovarian carcinoma after response to platinum therapy (ARIEL3): a randomised, double-blind, placebo-controlled, phase 3 trial

scientific article published on 12 September 2017

In more languages

Statements

scholarly article

1 reference

Europe PubMed Central

PMC publication ID

20 June 2018

http://europepmc.org/abstract/PMC/5901715

Rucaparib maintenance treatment for recurrent ovarian carcinoma after response to platinum therapy (ARIEL3): a randomised, double-blind, placebo-controlled, phase 3 trial (English)

1 reference

Europe PubMed Central

PMC publication ID

20 June 2018

http://europepmc.org/abstract/PMC/5901715

phase III clinical trial

0 references

1 reference

based on heuristic

inferred from title

1 reference

based on heuristic

inferred from title

ovarian carcinoma

1 reference

based on heuristic

inferred from title

Jesus Garcia-donas

object named as

Jesus Garcia-Donas

18

0 references

Alexandra Leary

object named as

Alexandra Leary

11

0 references

object named as

Iain A McNeish

22

0 references

Domenica Lorusso

3

object named as

Domenica Lorusso

1 reference

Europe PubMed Central

PMC publication ID

20 June 2018

Giovanni Scambia

10

object named as

Giovanni Scambia

1 reference

Europe PubMed Central

PMC publication ID

20 June 2018

http://europepmc.org/abstract/PMC/5901715

Carol Aghajanian

4

object named as

Carol Aghajanian

1 reference

Europe PubMed Central

PMC publication ID

20 June 2018

http://europepmc.org/abstract/PMC/5901715

Jeffrey Dean Isaacson

26

object named as

Jeff Isaacson

0 references

author name string

Robert L Coleman

1

1 reference

Europe PubMed Central

PMC publication ID

20 June 2018

http://europepmc.org/abstract/PMC/5901715

Amit M Oza

2

1 reference

Europe PubMed Central

PMC publication ID

20 June 2018

http://europepmc.org/abstract/PMC/5901715

Ana Oaknin

5

1 reference

Europe PubMed Central

PMC publication ID

20 June 2018

http://europepmc.org/abstract/PMC/5901715

Andrew Dean

6

1 reference

Europe PubMed Central

PMC publication ID

20 June 2018

http://europepmc.org/abstract/PMC/5901715

Nicoletta Colombo

7

1 reference

Europe PubMed Central

PMC publication ID

20 June 2018

http://europepmc.org/abstract/PMC/5901715

Johanne I Weberpals

8

1 reference

Europe PubMed Central

PMC publication ID

20 June 2018

http://europepmc.org/abstract/PMC/5901715

Andrew Clamp

9

1 reference

Europe PubMed Central

PMC publication ID

20 June 2018

http://europepmc.org/abstract/PMC/5901715

Robert W Holloway

12

1 reference

Europe PubMed Central

PMC publication ID

20 June 2018

http://europepmc.org/abstract/PMC/5901715

Margarita Amenedo Gancedo

13

1 reference

Europe PubMed Central

PMC publication ID

20 June 2018

http://europepmc.org/abstract/PMC/5901715

Peter C Fong

14

1 reference

Europe PubMed Central

PMC publication ID

20 June 2018

http://europepmc.org/abstract/PMC/5901715

Jeffrey C Goh

15

1 reference

Europe PubMed Central

PMC publication ID

20 June 2018

http://europepmc.org/abstract/PMC/5901715

David M O'Malley

16

1 reference

Europe PubMed Central

PMC publication ID

20 June 2018

http://europepmc.org/abstract/PMC/5901715

Deborah K Armstrong

17

1 reference

Europe PubMed Central

PMC publication ID

20 June 2018

http://europepmc.org/abstract/PMC/5901715

Elizabeth M Swisher

19

1 reference

Europe PubMed Central

PMC publication ID

20 June 2018

http://europepmc.org/abstract/PMC/5901715

Anne Floquet

20

1 reference

Europe PubMed Central

PMC publication ID

20 June 2018

http://europepmc.org/abstract/PMC/5901715

Gottfried E Konecny

21

1 reference

Europe PubMed Central

PMC publication ID

20 June 2018

http://europepmc.org/abstract/PMC/5901715

Clare L Scott

23

1 reference

Europe PubMed Central

PMC publication ID

20 June 2018

http://europepmc.org/abstract/PMC/5901715

Terri Cameron

24

1 reference

Europe PubMed Central

PMC publication ID

20 June 2018

http://europepmc.org/abstract/PMC/5901715

Lara Maloney

25

1 reference

Europe PubMed Central

PMC publication ID

20 June 2018

http://europepmc.org/abstract/PMC/5901715

Sandra Goble

27

1 reference

Europe PubMed Central

PMC publication ID

20 June 2018

http://europepmc.org/abstract/PMC/5901715

Caroline Grace

28

1 reference

Europe PubMed Central

PMC publication ID

20 June 2018

http://europepmc.org/abstract/PMC/5901715

Thomas C Harding

29

1 reference

Europe PubMed Central

PMC publication ID

20 June 2018

http://europepmc.org/abstract/PMC/5901715

Mitch Raponi

30

1 reference

Europe PubMed Central

PMC publication ID

20 June 2018

http://europepmc.org/abstract/PMC/5901715

James Sun

31

1 reference

Europe PubMed Central

PMC publication ID

20 June 2018

http://europepmc.org/abstract/PMC/5901715

Kevin K Lin

32

1 reference

Europe PubMed Central

PMC publication ID

20 June 2018

http://europepmc.org/abstract/PMC/5901715

Heidi Giordano

33

1 reference

Europe PubMed Central

PMC publication ID

20 June 2018

http://europepmc.org/abstract/PMC/5901715

Jonathan A Ledermann

34

1 reference

Europe PubMed Central

PMC publication ID

20 June 2018

http://europepmc.org/abstract/PMC/5901715

ARIEL3 investigators

35

1 reference

Europe PubMed Central

PMC publication ID

20 June 2018

http://europepmc.org/abstract/PMC/5901715

language of work or name

0 references

publication date

12 September 2017

1 reference

Europe PubMed Central

PMC publication ID

20 June 2018

http://europepmc.org/abstract/PMC/5901715

1 reference

Europe PubMed Central

PMC publication ID

20 June 2018

http://europepmc.org/abstract/PMC/5901715

390

1 reference

Europe PubMed Central

PMC publication ID

20 June 2018

http://europepmc.org/abstract/PMC/5901715

10106

1 reference

Europe PubMed Central

PMC publication ID

20 June 2018

http://europepmc.org/abstract/PMC/5901715

1949-1961

1 reference

Europe PubMed Central

PMC publication ID

20 June 2018

http://europepmc.org/abstract/PMC/5901715

Olaparib tablets as maintenance therapy in patients with platinum-sensitive, relapsed ovarian cancer and a BRCA1/2 mutation (SOLO2/ENGOT-Ov21): a double-blind, randomised, placebo-controlled, phase 3 trial

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5901715

22 June 2018

Bevacizumab and paclitaxel-carboplatin chemotherapy and secondary cytoreduction in recurrent, platinum-sensitive ovarian cancer (NRG Oncology/Gynecologic Oncology Group study GOG-0213): a multicentre, open-label, randomised, phase 3 trial

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5901715

22 June 2018

A Phase I-II Study of the Oral PARP Inhibitor Rucaparib in Patients with Germline BRCA1/2-Mutated Ovarian Carcinoma or Other Solid Tumors

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5901715

22 June 2018

Rucaparib in relapsed, platinum-sensitive high-grade ovarian carcinoma (ARIEL2 Part 1): an international, multicentre, open-label, phase 2 trial.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5901715

22 June 2018

Niraparib Maintenance Therapy in Platinum-Sensitive, Recurrent Ovarian Cancer

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5901715

22 June 2018

Cediranib in patients with relapsed platinum-sensitive ovarian cancer (ICON6): a randomised, double-blind, placebo-controlled phase 3 trial.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5901715

22 June 2018

Pan-cancer analysis of genomic scar signatures associated with homologous recombination deficiency suggests novel indications for existing cancer drugs

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5901715

22 June 2018

Genomic scars as biomarkers of homologous recombination deficiency and drug response in breast and ovarian cancers

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5901715

22 June 2018

Olaparib maintenance therapy in patients with platinum-sensitive relapsed serous ovarian cancer: a preplanned retrospective analysis of outcomes by BRCA status in a randomised phase 2 trial.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5901715

22 June 2018

Prediction of clinical drug-drug interactions of veliparib (ABT-888) with human renal transporters (OAT1, OAT3, OCT2, MATE1, and MATE2K).

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5901715

22 June 2018

Copy neutral loss of heterozygosity is more frequent in older ovarian cancer patients

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5901715

22 June 2018

Second-line treatment in advanced pancreatic cancer: a comprehensive analysis of published clinical trials

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5901715

22 June 2018

Patterns of genomic loss of heterozygosity predict homologous recombination repair defects in epithelial ovarian cancer

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5901715

22 June 2018

OCEANS: a randomized, double-blind, placebo-controlled phase III trial of chemotherapy with or without bevacizumab in patients with platinum-sensitive recurrent epithelial ovarian, primary peritoneal, or fallopian tube cancer

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5901715

22 June 2018

Definitions for response and progression in ovarian cancer clinical trials incorporating RECIST 1.1 and CA 125 agreed by the Gynecological Cancer Intergroup (GCIG).

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5901715

22 June 2018

New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1)

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5901715

22 June 2018

Workshop: options for therapy in ovarian cancer

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5901715

22 June 2018

The medical dictionary for regulatory activities (MedDRA).

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5901715

22 June 2018

In vitro assessment of the roles of drug transporters in the disposition and drug-drug interaction potential of olaparib.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5901715

15 August 2018

A new index of priority symptoms in advanced ovarian cancer.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5901715

15 August 2018

Timing isn't everything: an analysis of when to start salvage chemotherapy in ovarian cancer

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5901715

15 August 2018

Olaparib Maintenance Therapy in Platinum-Sensitive Relapsed Ovarian Cancer

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5901715

1 December 2018

Hy's law: predicting serious hepatotoxicity

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2817%2932440-6

7 January 2021

based on heuristic

inferred from DOI database lookup

Identifiers

10.1016/S0140-6736(17)32440-6

1 reference

Europe PubMed Central

PMC publication ID

20 June 2018

http://europepmc.org/abstract/PMC/5901715

PMC publication ID

1 reference

Europe PubMed Central

PMC publication ID

20 June 2018

http://europepmc.org/abstract/PMC/5901715

PubMed publication ID

1 reference

Europe PubMed Central

PMC publication ID

20 June 2018

http://europepmc.org/abstract/PMC/5901715

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q46270437&oldid=2191050037"